Ortho Evra contraceptive transdermal birth control patch label update

The U.S. Food and Drug Administration (FDA) approved additional changes to the Ortho Evra Contraceptive Transdermal (Skin) Patch label to include the results of a new epidemiology study that found that users of the birth control patch were at higher risk of developing serious blood clots, also known as venous thromboembolism (VTE), than women using birth control pills. VTE can lead to pulmonary embolism.

The label changes are based on a study conducted by the Boston Collaborative Drug Surveillance Program (BCDSP) on behalf of Johnson and Johnson. The patch was studied in women aged 15-44. These recent findings support an earlier study that also said women in this group were at higher risk for VTE.

"For women that choose to use contraceptives, it is important that they thoroughly discuss with their health care providers the risks and benefits involved," said Janet Woodcock, M.D., the FDA's deputy commissioner for scientific and medical programs, chief medical officer, and acting director of the Center for Drug Evaluation and Research.

Ortho Evra is a prescription patch that releases ethinyl estradiol (an estrogen hormone) and norelgestromin (a progestin hormone) through the skin into the blood stream. Because the hormones are processed by the body differently than hormones from birth control pills, women using the product will be exposed to about 60 percent more estrogen than if they were using typical birth control pills containing 35 micrograms of estrogen. Increased levels of estrogen may increase the risk of side effects, including VTE. Women should discuss with their health care provider the possible increased risk of VTE with Ortho Evra, which is applied once a week, and balance this risk against the increased chance of pregnancy if women do not take their birth control pill daily.

The FDA believes that Ortho Evra is a safe and effective method of contraception when used according to the labeling, which recommends that women with concerns or risk factors for serious blood clots talk with their health care provider about using Ortho Evra versus other contraceptive options.

The Ortho Evra Contraceptive Transdermal Patch is manufactured by Ortho McNeil Pharmaceuticals, a division of Johnson and Johnson.

(Published at Health News Track on January 18, 2008 - 354 days ago)

Birth control article/news source:

U.S. Food and Drug Administration - read other health news articles from U.S. Food and Drug Administration and health news articles from USA.

»» Lhx2 creator gene for brain tissue repair
«« Canadians support ban on smoking in cars with kids

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.
We comply with the HONcode principles for trustworthy health information, verify here.
www.healthnewstrack.com - About us, Editorial team, Advertising, Jobs, Links, Privacy policy, Disclaimer, Feedback,
Site map, List health news, Health news organizations, Health news world, Accessibility, Glossary, Testimonials, Blog
Mobile/PDA Submit press release
© 2007-2008 HealthNewstrack.com
Track Health News Daily
3.18